Murali Janakiram

Assistant Professor

University of Minnesota System

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Murali Janakiram is an Assistant Professor at the University of Minnesota System in the United States. His research focuses on multiple myeloma, particularly regarding CAR T-cell therapies and associated clinical outcomes. Recent publications include analyses on prescribing patterns, safety and efficacy of treatments, and economic considerations in managing the disease.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Kenneth Carson

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Geoffrey Shouse

Assistant Clinical Professor

City Of Hope National Medical Center

UNITED STATES

View details

Christopher Wilke

University of Minnesota

UNITED STATES

View details

Siddharth Karanth

Health Solutions

UNITED STATES

View details

Lawrence Liu

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES

View details

John Sloan

Associate Professor

Boston University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Murali Janakiram

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Cumulative Excess Body Mass Index and MGUS Progression to Myeloma.

Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Impact of Human T Cell Lymphotropic Virus Type 1 and 2 Infection on Survival Following Stem Cell Transplantation

Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis

Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma

Collaborators (6)

Kenneth Carson

Geoffrey Shouse

Christopher Wilke

Siddharth Karanth

Lawrence Liu

John Sloan

Make your next move.